Literature DB >> 33230343

Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates.

Molly E Gallagher1, Andrew J Sieben2, Kristin N Nelson3, Alicia N M Kraay3, Walter A Orenstein4,5, Ben Lopman3, Andreas Handel6, Katia Koelle7,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33230343     DOI： 10.1038/s41591-020-01172-x

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  1 in total

1.  Field evaluation of vaccine efficacy.

Authors:  W A Orenstein; R H Bernier; T J Dondero; A R Hinman; J S Marks; K J Bart; B Sirotkin
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408
  1 in total
  13 in total

1.  Optimal control of the spatial allocation of COVID-19 vaccines: Italy as a case study.

Authors:  Joseph Chadi Lemaitre; Damiano Pasetto; Mario Zanon; Enrico Bertuzzo; Lorenzo Mari; Stefano Miccoli; Renato Casagrandi; Marino Gatto; Andrea Rinaldo
Journal:  PLoS Comput Biol       Date:  2022-07-08       Impact factor: 4.779

2.  Population-Level Effectiveness of COVID-19 Vaccination Program in the United States: Causal Analysis Based on Structural Nested Mean Model.

Authors:  Rui Wang; Jiahao Wang; Taojun Hu; Xiao-Hua Zhou
Journal:  Vaccines (Basel)       Date:  2022-05-05

3.  COVID-19 Vaccine Allocation: Modeling Health Outcomes and Equity Implications of Alternative Strategies.

Authors:  Maddalena Ferranna; Daniel Cadarette; David E Bloom
Journal:  Engineering (Beijing)       Date:  2021-05-03       Impact factor: 7.553

4.  Population immunity and vaccine protection against infection.

Authors:  Eyal Leshem; Benjamin Alan Lopman
Journal:  Lancet       Date:  2021-04-23       Impact factor: 79.321

5.  Vaccination and Quarantine Effect on COVID-19 Transmission Dynamics Incorporating Chinese-Spring-Festival Travel Rush: Modeling and Simulations.

Authors:  Yukun Zou; Wei Yang; Junjie Lai; Jiawen Hou; Wei Lin
Journal:  Bull Math Biol       Date:  2022-01-10       Impact factor: 3.871

6.  Quantifying the Population-Level Effect of the COVID-19 Mass Vaccination Campaign in Israel: A Modeling Study.

Authors:  Ido Somekh; Wasiur R KhudaBukhsh; Elisabeth Dowling Root; Lital Keinan Boker; Grzegorz Rempala; Eric A F Simões; Eli Somekh
Journal:  Open Forum Infect Dis       Date:  2022-02-18       Impact factor: 4.423

7.  Exploring the risk factors of COVID-19 Delta variant in the United States based on Bayesian spatio-temporal analysis.

Authors:  Shaopei Ma; Xueliang Zhang; Kai Wang; Liping Zhang; Lei Wang; Ting Zeng; Man-Lai Tang; Maozai Tian
Journal:  Transbound Emerg Dis       Date:  2022-07-09       Impact factor: 4.521

8.  Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality.

Authors:  Mehul D Patel; Erik Rosenstrom; Julie S Ivy; Maria E Mayorga; Pinar Keskinocak; Ross M Boyce; Kristen Hassmiller Lich; Raymond L Smith; Karl T Johnson; Paul L Delamater; Julie L Swann
Journal:  JAMA Netw Open       Date:  2021-06-01

9.  COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact.

Authors:  David A Swan; Chloe Bracis; Joshua T Schiffer; Dobromir Dimitrov; Holly Janes; Mia Moore; Laura Matrajt; Daniel B Reeves; Eileen Burns; Deborah Donnell; Myron S Cohen
Journal:  Sci Rep       Date:  2021-07-30       Impact factor: 4.379

10.  A framework for monitoring population immunity to SARS-CoV-2.

Authors:  Benjamin A Lopman; Kayoko Shioda; Quan Nguyen; Stephen J Beckett; Aaron J Siegler; Patrick S Sullivan; Joshua S Weitz
Journal:  Ann Epidemiol       Date:  2021-08-21       Impact factor: 3.797
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.